Table 1 Correlation between NTRS group and clinicopathological factors of glioma patients in the two cohorts
Features | Training set TCGA RNA-seq cohort (n = 660) | Validation set CGGA RNA-seq cohort (n = 668) | ||||
|---|---|---|---|---|---|---|
NTRSLow(n = 391) | NTRSHigh(n = 269) | p-value | NTRSLow(n = 281) | NTRSHigh(n = 387) | p-value | |
Age | ||||||
 Mean (range) | 41 (17–75) | 56 (14–89) | < 0.001*** | 41 (12–69) | 45 (11–76) | < 0.001*** |
Gender | ||||||
 Female | 170 | 108 | 0.38 | 135 | 153 | < 0.05* |
 Male | 219 | 161 |  | 146 | 234 |  |
 NA | 2 | 0 |  |  |  |  |
WHO Grade | ||||||
 II | 224 | 19 | < 0.001*** | 106 | 74 | < 0.001*** |
 III | 163 | 96 |  | 136 | 115 |  |
 IV | 3 | 154 |  | 39 | 198 |  |
 NA | 1 | 0 |  |  |  |  |
IDH status | ||||||
 Wildtype | 12 | 221 | < 0.001*** | 44 | 233 | < 0.001*** |
 Mutant | 373 | 43 |  | 228 | 115 |  |
 NA | 6 | 5 |  | 9 | 39 |  |
Chr.1p/19q status | ||||||
 Noncodeletion | 223 | 249 | < 0.001*** | 162 | 299 | < 0.001*** |
 Codeletion | 163 | 3 |  | 117 | 24 |  |
 NA | 5 | 17 |  | 2 | 64 |  |
Histology | ||||||
 Astrocytoma | 120 | 71 | < 0.001*** | 57 | 67 | < 0.001*** |
 Oligodendroglioma | 168 | 17 |  | 52 | 29 |  |
 Oligoastrocytoma | 100 | 27 |  | 133 | 93 |  |
 Glioblastoma | 3 | 154 |  | 39 | 198 |  |
MGMT promoter status | ||||||
 Methylated | 352 | 111 | < 0.001*** | / | / |  |
 Unmethylated | 30 | 123 |  | / | / |  |
 NA | 9 | 35 |  | / | / |  |
Chr.7.gain&Chr.10.loss | ||||||
 Yes | 1 | 146 | < 0.001*** | / | / |  |
 No | 380 | 106 |  | / | / |  |
 NA | 10 | 17 |  | / | / |  |
Chr.19&20 gain | ||||||
 Non-gain | 381 | 222 | < 0.001*** | / | / |  |
 Gain | 0 | 30 |  | / | / |  |
 NA | 10 | 17 |  | / | / |  |
ATRX status | ||||||
 Wildtype | 227 | 218 | < 0.001*** | / | / |  |
 Mutant | 155 | 33 |  | / | / |  |
 NA | 9 | 18 |  | / | / |  |